Pharma-backed petition urges FDA to change policy on public release of drug rejection letters

A law firm representing an unnamed pharmaceutical company has filed a petition asking the FDA to revise its new practice of publishing partially redacted drug rejection letters.

The petition argues that the public release of these documents could expose confidential information and potentially harm competitive dynamics within the industry.

The filing marks the first time the FDA has faced organized criticism from the pharmaceutical sector over this transparency initiative, highlighting growing tension between regulatory openness and commercial confidentiality.

Stakeholders are awaiting the agency's response, which could shape how future drug review communications are handled.